News
TCMD
12.92
+0.62%
0.08
Tactile Medical to Present at the William Blair 44th Annual Growth Stock Conference
Tactile Systems Technology, Inc. Will participate in the William Blair 44th Annual Growth Stock Conference in Chicago, IL on June 4th and 6th. The company provides therapies for people with chronic disorders. Management will also participate in a fireside chat on Tuesday, June 4.
Barchart · 1d ago
Weekly Report: what happened at TCMD last week (0513-0517)?
Weekly Report · 2d ago
Weekly Report: what happened at TCMD last week (0506-0510)?
Weekly Report · 05/13 10:43
Tactile Systems: Report of proposed sale of securities
Press release · 05/08 20:12
Oppenheimer Remains a Buy on Tactile Systems Technology (TCMD)
TipRanks · 05/07 12:18
Tactile Systems Technology (TCMD) Gets a Buy from Piper Sandler
TipRanks · 05/07 12:07
TCMD Stock Earnings: Tactile Systems Tech Beats EPS, Beats Revenue for Q1 2024
Tactile Systems Tech reported earnings per share of -5 cents for the first quarter of 2024. The company reported revenue of $61.09 million. This was 3.24% better than the analyst estimate for the same period. Tactile systems tech also reported results for the fourth quarter of 2015.
Investorplace · 05/07 00:57
Tactile Systems Technology, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended: March 31, 2024
Press release · 05/07 00:26
Tactile Systems Technology Continues To Expect FY24 Total Revenue Of $300M-$305M, Est $302.9M
Benzinga · 05/06 21:07
Tactile Systems Technology Inc reports results for the quarter ended in March - Earnings Summary
Tactile Systems Technology Inc reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 9 cents per share. Revenue fell 9.4% to $53.31 million from the same quarter last year. The average analyst rating on the shares is "strong buy"
Reuters · 05/06 21:02
Tactile Systems Technology GAAP EPS of -$0.09 misses by $0.01, revenue of $61.1M beats by $1.87M
Tactile Systems Technology, Inc. GAAP EPS of -$0.09 misses by $0.01, revenue of $61.1M beats by $1.87M. Q1 GAAP revenue was up 3.9% from a year ago.
Seeking Alpha · 05/06 20:27
BRIEF-Tactile Systems Technology Q1 Adjusted EBITDA USD 1 Million
Reuters · 05/06 20:05
TACTILE SYSTEMS TECHNOLOGY INC: CONTINUES TO EXPECT 2024 TOTAL REVENUE IN RANGE OF $300 MLN TO $305 MLN
Reuters · 05/06 20:05
TACTILE SYSTEMS TECHNOLOGY INC <TCMD.O> FY2024 REV VIEW $302.9 MLN -- LSEG IBES DATA
Reuters · 05/06 20:05
Press Release: Tactile Systems Technology, Inc. -2-
These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. The Company believes these measures are useful to investors as supplemental information. The company does not use Adjusted EBITDA as a measure of free cash flow for management's discretionary use.
Dow Jones · 05/06 20:05
*Tactile Systems Tech 1Q Rev $61.1M >TCMD
Dow Jones · 05/06 20:05
*Tactile Systems Tech 1Q Loss/Shr 9c >TCMD
Dow Jones · 05/06 20:05
*Tactile Systems Tech Sees FY Rev $300M-$305M >TCMD
Dow Jones · 05/06 20:05
Press Release: Tactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results
Tactile Systems Technology, Inc. Reports First Quarter 2024 Financial Results Reaffirms Full Year 2024 Outlook. Total revenue in the first quarter of 2024 increased 4% year-over-year to $61.1 million. Lymphedema product revenue increased 5% and airway clearance product revenue decreased 4%. The company completed enrollment of 235 patients in a clinical trial.
Dow Jones · 05/06 20:05
*Tactile Systems Tech 1Q Loss $2.21M >TCMD
Dow Jones · 05/06 20:05
More
Webull provides a variety of real-time TCMD stock news. You can receive the latest news about Tactile Systems through multiple platforms. This information may help you make smarter investment decisions.
About TCMD
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.